The U.S. Food and Drug Administration (FDA) approved of SKINVIVE by JUVÉDERM from Allergan Aesthetics to reduce neck lines for the improvement of neck appearance in adults over the age of 21 the company announced on June 16, 2026.
The news comes after the AbbVie company submitted a supplemental premarket approval application (PMA) last year after the supplement was originally approved by the FDA in 2023 for smoothness of the cheeks.
Related: Allergan Aesthetics Seeks FDA Approval to Expand Skinvive by Juvéderm for Neck Rejuvenation
SKINVIVE by JUVÉDERM is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by tech-neck — or neck wrinkles that develop due to natural aging, sun damage or weight loss.
According to the press release, SKINVIVE by JUVÉDERM reduces neck lines by helping the skin retain its natural moisture, softness, and smoothness. Treatment is minimally invasive with little to no downtime and is administered using an ultrafine needle or cannula. The product contains a small amount of local anesthetic (lidocaine) to support patient comfort during treatment. Results last six months with optimal treatment.
"The approval of SKINVIVE by JUVÉDERM for horizontal neck wrinkles reflects Allergan Aesthetics' commitment to developing science-driven innovations that address meaningful unmet aesthetic needs," said Darin Messina, Ph.D., senior vice president, aesthetics R&D, AbbVie. "This approval expands our portfolio of lower face and neck treatment options and gives patients and aesthetic providers a first-of-its-kind treatment option for improving neck skin quality and reducing the appearance of neck lines.
